G-CSF in Preventing Neutropenia in Patients With Solid Tumors Who Are Receiving Chemotherapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

140 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RATIONALE: Colony-stimulating factors, such as G-CSF, may increase the number of white blood cells found in bone marrow or peripheral blood and may prevent persistent neutropenia in patients receiving chemotherapy. It is not yet known which regimen of G-CSF may be more effective in preventing neutropenia.

PURPOSE: This randomized phase III trial is comparing two different regimens of G-CSF to see how well it works in preventing persistent neutropenia in patients with solid tumors who are receiving chemotherapy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer

NCT00771433

Breast Cancer Chemotherapeutic Agent Toxicity Neutropenia

COMPLETED PHASE2

Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer

NCT04101760

Chemotherapy-induced Neutropenia Febrile Neutropenia, Drug-Induced Epithelial Ovarian Cancer +6 more

UNKNOWN PHASE3

Antibiotic Therapy With or Without G-CSF in Treating Children With Neutropenia and Fever Caused by Chemotherapy

NCT00003739

Fever, Sweats, and Hot Flashes Neutropenia Unspecified Childhood Solid Tumor, Protocol Specific

COMPLETED PHASE3

Use of Biosimilar Nivestim® to Prevent Chemo-induced Neutropenia. Real Life Study

NCT02454530

Chemotherapy-Induced Neutropenia

TERMINATED

Various G-CSF Regimens to Prevent Infection During Chemotherapy

NCT00536081

Breast Cancer Chemotherapy Febrile Neutropenia

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

OBJECTIVES:

Primary

* Determine the efficacy of filgrastim (G-CSF) in preventing persistent moderate neutropenia in patients with solid tumors while maintaining chemotherapy courses.

Secondary

* Compare the tolerability of 2 regimens of G-CSF in these patients.
* Determine the number of courses of G-CSF needed in each regimen.
* Evaluate the frequency of infections.
* Determine dose intensity.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I: Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.
* Arm II: Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chemotherapeutic Agent Toxicity Neutropenia Unspecified Adult Solid Tumor, Protocol Specific

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm I

Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily for 6 days beginning 1 week after the start of chemotherapy (days 7-12). If chemotherapy begins on day 8, patients receive G-CSF SC on days 9-14.

Group Type EXPERIMENTAL

filgrastim

Intervention Type BIOLOGICAL

Given subcutaneously

Arm II

Patients receive G-CSF SC every 2 days on days 10-20 for up to 6 injections.

Group Type EXPERIMENTAL

filgrastim

Intervention Type BIOLOGICAL

Given subcutaneously

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

filgrastim

Given subcutaneously

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

DISEASE CHARACTERISTICS:

* Diagnosis of solid tumor
* Receiving chemotherapy in any line of treatment (adjuvant or metastatic)

* Chemotherapy courses repeating every 21 days or beginning on day 8 allowed
* Received at least 2 prior courses of chemotherapy
* Moderate neutropenia (grade 1-3) leading to a delay of the first course by ≥ 7 days or a delay of the second course of treatment

PATIENT CHARACTERISTICS:

* Not pregnant or nursing
* Fertile patients must use effective contraception
* No known hypersensitivity to filgrastim (G-CSF) or any of its components
* No severe immunodepression
* No malignant hematological disease
* No history of psychiatric illness
* No patients deprived of liberty or under guardianship
* No psychological, familial, social, or geographical reasons preventing follow-up

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No